{"schema_version":"secwatch.filing_event.v1","accession":"0001145197-23-000004","form_type":"8-K","ticker":"PODD","cik":"0001145197","company_name":"INSULET CORP","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.982938+00:00","generated_at":"2026-06-19T13:11:59.049187+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Insulet acquires ~400 patents from Bigfoot Biomedical for $25M, licenses others","bullets":["Acquired ~400 patents and a significant number of patent applications from Bigfoot; $25M one-time fee.","Insulet gets exclusive, sublicensable license to Step-In Patents in pump-based drug delivery (Insulet Field).","Bigfoot retains exclusive license to same patents for injector-based drug delivery (Bigfoot Field).","Non-Step-In Patents are licensed non-exclusively to Insulet in Insulet Field.","Insulet may take possession of Bigfoot's molds and tooling for Insulet Field within one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001145197-23-000004","json":"https://secwatch.observer/filing/0001145197-23-000004.json","markdown":"https://secwatch.observer/filing/0001145197-23-000004.md","text":"https://secwatch.observer/filing/0001145197-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1145197/000114519723000004/0001145197-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1145197/000114519723000004/podd-20230209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:11:59.049187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf1407ca24621dbf9d746483dd1a8b2d4af62087","claim":"INSULET CORP entered into Patent Assignment and License Agreement with Bigfoot Biomedical, Inc. and Patients Pending, Ltd. (collectively, \"Bigfoot\") (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, Insulet Corporation (the “Company”) entered into a Patent Assignment and License Agreement with Bigfoot Biomedical, Inc. and Patients Pending, Ltd. (collectively, “Bigfoot”) pursuant to which the Company acquired from Bigfoot approximately 400 patents as well as a significant number of patent applications, and licensed a significant number of additional patents and patent applications on a fully paid-up exclusive or non-exclusive basis.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1145197/000114519723000004/0001145197-23-000004-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Bigfoot Biomedical, Inc. and Patients Pending, Ltd. (collectively, \"Bigfoot\")"},{"label":"Effective","value":"2023-02-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}